Advertisement
Screener

Septerna, Inc. (SEPN) Cash Flow Breakdown

Septerna, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Septerna, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $110.19M came in.
  • Fiscal year ended 2025-12-31: from investing, $229.35M went out.
  • Fiscal year ended 2025-12-31: from financing, $1.69M came in.
  • Fiscal year ended 2025-12-31: change in cash, $117.47M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31$110.19M-$229.35M$973.00K$716.00K*-$117.47M
2024-12-31-$67.47M-$160.60M$52.00K$377.73M*$149.71M
2023-12-31-$38.72M$22.12M$0.00$74.52M*$57.92M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$22.18M*$18.41M*$2.08M*$14.74M*
2026-03-31-$25.63M-$23.82M$333.00K-$49.12M
2025-12-31-$14.99M*-$185.30M*$304.00K*$717.00K*
2025-09-30$168.81M*-$38.39M*$264.00K*
2025-06-30-$20.29M*-$786.00K*$339.00K*
2025-03-31-$23.34M-$4.87M$66.00K-$28.15M
2024-12-31-$20.96M*-$133.24M*$36.00K*$304.12M*
2024-09-30-$16.81M*-$24.79M*$5.00K*-$1.33M*
2024-06-30-$12.99M*-$12.13M*
2024-03-31-$16.71M$9.57M-$7.14M
2023-12-31-$8.80M*-$1.24M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xencor Inc (XNCR)United States$1.776B-7.33
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82